Our Authors
Associate Professor Prue Cormie, Australian Catholic University Associate Professor Prue Cormie is an accredited exercise physiologist whose research and clinical work focuses on the application of exercise as medicine for the management of cancer. She aims to enhance the lives of people with cancer through innovative research and effectively translating research into practice. More information on her work is available here: www.iha.acu.edu.au/cancer.4 Articles
Ian Davis is Professor of Medicine, Monash University and Eastern Health Head, Eastern Health Clinical School and Medical oncologist, Eastern Health Chair. He is also Chair of the ANZUP Cancer Trials Group.4 Articles
Dr Prunella Blinman is a medical oncologist at the Concord Cancer Centre who specialises in the management of thoracic and gastrointestinal cancers. She is also a clinical senior lecturer at the Sydney Medical School, and an active researcher and supervisor of postgraduate students. She enjoys attending the ASCO Annual Meeting for the educational and networking opportunities.4 Articles
Dr Hilda High is medical oncologist specialising in cancer genetics. She has worked with familial cancer services at the Prince of Wales Hospital, Westmead Hospital and Royal North Shore Hospitals and now works with Sydney Cancer Genetics through rooms at the SAN, in Ultimo in Sydney and via telehealth to rural and regional Australia.3 Articles
Behavioural scientist with extensive experience in cancer clinical research, in particular post-cancer diagnosis supportive care and psycho-oncology.3 Articles
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system.3 Articles
Emeritus Professor Ian Maddocks is an eminent palliative care specialist and a passionate advocate for world peace. A specialist physician in the Australian Administration of Papua New Guinea for 14 years, he became Foundation Dean of the Faculty of Medicine at the University of Papua New Guinea in 1971. Since 1982 he has worked with medical groups seeking to eliminate nuclear weapons. Ian was President of the Medical Association for Prevention of War when it received an Australian Peace Medal, and Vice-President of International Physicians for Prevention of Nuclear War when it received the Nobel Prize for Peace in 1985. Since 1980 he has advocated improved care for the dying, and was first Chair of Palliative Care at Flinders University, first President of the Australian Association for Hospice and Palliative Care and first President of the Australian and New Zealand Society for Palliative Medicine. Recipient of the inaugural Bethlehem Griffiths Medal for research in palliative care, Ian is recognised internationally for his work in palliative care, tropical and preventative medicine. Now Emeritus Professor at Flinders University, he continues daily care for the terminally ill.2 Articles
BXTAccelyon (BXTA) is the leading low-dose rate brachytherapy (LDR-B) partner to hospitals and clinics worldwide, and distribution partner for the PrecisionPoint™ freehand transperineal prostate biopsy system.2 Articles
A/Prof. Ben Chua is a consultant Radiation Oncologist at GenesisCare Rockhampton and Brisbane (Chermside and Wesley). He qualified obtained his radiation oncology fellowship in 2015 after training in Queensland and regional New South Wales, including a fellowship in head & neck cancer. He also has an interest in complex skin, CNS and haematological malignancies. A/Prof. Chua has a conjoint appointment at the University of Queensland with an active academic portfolio, including over $2m in competitive grant funding, supervision of higher degree students, leadership of clinical trials as a chairperson and principal investigator, publications in international medical journals and presentations at international meetings.2 Articles
Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialisation of innovative therapies for the treatment of cancer and inflammatory diseases through next-generation solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.2 Articles